{"id":"placebo-5-fluorouracil-leucovorin","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"30-40","effect":"Mucositis / stomatitis"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"20-30","effect":"Nausea and vomiting"},{"rate":"10-20","effect":"Hand-foot syndrome"},{"rate":"10-20","effect":"Alopecia"},{"rate":"20-30","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"5-Fluorouracil (5-FU) acts as a prodrug that is converted intracellularly to active metabolites, primarily inhibiting thymidylate synthase to block dTMP synthesis and DNA replication. Leucovorin (folinic acid) provides reduced folate cofactors that increase the stability and potency of the 5-FU-thymidylate synthase inhibitory complex, thereby enhancing cytotoxic effects. This combination is a standard chemotherapy regimen used across multiple cancer types.","oneSentence":"5-Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA, disrupting nucleotide synthesis and cancer cell division, while leucovorin enhances its efficacy by stabilizing the drug-enzyme complex.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:22.567Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (adjuvant or metastatic)"},{"name":"Gastric cancer"},{"name":"Breast cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT07409272","phase":"PHASE3","title":"A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2026-02-17","conditions":"Pancreatic Cancer, Metastatic Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma","enrollment":614},{"nctId":"NCT06901531","phase":"PHASE3","title":"A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer","status":"RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2025-05-22","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":500},{"nctId":"NCT03221426","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-10-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":1007},{"nctId":"NCT04882241","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-29","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":120},{"nctId":"NCT05983367","phase":"PHASE2","title":"A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"Inspirna, Inc.","startDate":"2023-10-10","conditions":"Colorectal Cancer, Metastatic Colon Cancer","enrollment":76},{"nctId":"NCT05052801","phase":"PHASE3","title":"Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-07","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":547},{"nctId":"NCT03504397","phase":"PHASE3","title":"A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy in Adults With Gastric Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2018-06-21","conditions":"Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer, Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer, Metastatic Gastric Adenocarcinoma or Cancer","enrollment":565},{"nctId":"NCT07391163","phase":"NA","title":"Protective Effect of N-acetylcysteine on Oxaliplatin-Induced Neuropathy in Colorectal Cancer","status":"COMPLETED","sponsor":"Tanta University","startDate":"2024-01-01","conditions":"Colorectal Cancer","enrollment":46},{"nctId":"NCT06093425","phase":"PHASE3","title":"Combination of Osemitamab (TST001), Pembrolizumab and Chemotherapy as First-line Therapy in Advanced or Metastatic GC/GEJ Adenocarcinoma","status":"NOT_YET_RECRUITING","sponsor":"Suzhou Transcenta Therapeutics Co., Ltd.","startDate":"2026-06-30","conditions":"Gastric Cancer, Gastroesophageal-junction Cancer, Advanced Cancer","enrollment":820},{"nctId":"NCT05111626","phase":"PHASE3","title":"Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2022-03-14","conditions":"Gastric Cancer, Gastroesophageal Junction Adenocarcinoma","enrollment":515},{"nctId":"NCT07028424","phase":"PHASE2","title":"PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment","status":"NOT_YET_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2025-07","conditions":"PDAC - Pancreatic Ductal Adenocarcinoma","enrollment":206},{"nctId":"NCT06055179","phase":"NA","title":"XCHT for Irinotecan-Induced Gut Toxicities (Randomized Controlled Trial)","status":"RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2024-03-08","conditions":"Xiao Chai Hu Tang, Irinotecan-induced Diarrhea","enrollment":98},{"nctId":"NCT05712356","phase":"PHASE2","title":"A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lisata Therapeutics, Inc.","startDate":"2023-08-24","conditions":"Cholangiocarcinoma, Gallbladder Cancer, Gallbladder Carcinoma","enrollment":67},{"nctId":"NCT05624138","phase":"PHASE3","title":"The Possible Protective Role of Ketotifen Against Oxaliplatin Induced Peripheral Neuropathy","status":"RECRUITING","sponsor":"Tanta University","startDate":"2022-11-09","conditions":"Neuropathy;Peripheral","enrollment":64},{"nctId":"NCT04245865","phase":"PHASE2","title":"Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vejle Hospital","startDate":"2020-06-26","conditions":"Colorectal Cancer Metastatic","enrollment":83},{"nctId":"NCT04825288","phase":"PHASE1, PHASE2","title":"XB2001 in Combination With ONIVYDE + 5-FU/LV (+Folinic Acid) in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"XBiotech, Inc.","startDate":"2021-05-27","conditions":"Pancreatic Cancer","enrollment":76},{"nctId":"NCT04607668","phase":"PHASE3","title":"Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):","status":"TERMINATED","sponsor":"G1 Therapeutics, Inc.","startDate":"2021-01-06","conditions":"Colorectal Cancer Metastatic, Myelosuppression-Adult, Chemotherapeutic Toxicity","enrollment":326},{"nctId":"NCT04210115","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-02-28","conditions":"Esophageal Squamous Cell Carcinoma (ESCC), Gastroesophageal Junction Carcinoma (GEJC), Esophageal Adenocarcinoma (EAC)","enrollment":703},{"nctId":"NCT03941093","phase":"PHASE3","title":"Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer","status":"COMPLETED","sponsor":"Kyntra Bio","startDate":"2019-05-10","conditions":"Pancreatic Cancer Non-resectable","enrollment":284},{"nctId":"NCT02705300","phase":"PHASE2","title":"Side Effects to FOLFOXIRI + Tocotrienol/Placebo as First Line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Vejle Hospital","startDate":"2016-05-06","conditions":"Colorectal Cancer","enrollment":70},{"nctId":"NCT05251727","phase":"PHASE1","title":"Assess Safety and Tolerability of ART-123 + FOLFOX + Bevacizumab in Metastatic Colorectal Cancer Patients","status":"TERMINATED","sponsor":"Veloxis Pharmaceuticals","startDate":"2022-03-24","conditions":"Chemotherapy-induced Peripheral Neuropathy","enrollment":77},{"nctId":"NCT06509880","phase":"PHASE1, PHASE2","title":"Immunosurveillance for Metastatic Colorectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"MIPO Clinic","startDate":"2024-07-15","conditions":"Monitoring, Immunologic","enrollment":200},{"nctId":"NCT03694522","phase":"PHASE2","title":"A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Five Prime Therapeutics, Inc.","startDate":"2018-09-14","conditions":"Gastric Cancer","enrollment":155},{"nctId":"NCT05074589","phase":"PHASE3","title":"Irinotecan Liposome in Combination With 5-FU/LV Versus 5-FU/LV in Second-line Therapy for Gemcitabine-Refractory Pancreatic Cancer","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2018-01-25","conditions":"Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy","enrollment":298},{"nctId":"NCT05669521","phase":"PHASE2","title":"Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690","status":"UNKNOWN","sponsor":"Tosk, Inc.","startDate":"2022-06-15","conditions":"Mucositis","enrollment":24},{"nctId":"NCT04233151","phase":"PHASE3","title":"QL1203 In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy and Safety","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2020-01-20","conditions":"Metastatic Colorectal Cancer","enrollment":590},{"nctId":"NCT02344810","phase":"PHASE1, PHASE2","title":"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer","status":"WITHDRAWN","sponsor":"Eastern Cooperative Oncology Group","startDate":"2015-03-06","conditions":"Adenocarcinoma of the Esophagus, Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach","enrollment":""},{"nctId":"NCT01150045","phase":"PHASE3","title":"Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery","status":"UNKNOWN","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2010-06","conditions":"Colorectal Cancer","enrollment":2527},{"nctId":"NCT03254394","phase":"PHASE1, PHASE2","title":"Lidocaine for Oxaliplatin-induced Neuropathy","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2017-09-15","conditions":"Neuropathy, Painful, Chemotherapy-induced Peripheral Neuropathy, Colorectal Cancer","enrollment":26},{"nctId":"NCT01896531","phase":"PHASE2","title":"A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2013-08-14","conditions":"Gastric Cancer","enrollment":153},{"nctId":"NCT03130790","phase":"PHASE2, PHASE3","title":"Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line)","status":"COMPLETED","sponsor":"ASLAN Pharmaceuticals","startDate":"2017-08-31","conditions":"Gastric Cancer","enrollment":52},{"nctId":"NCT01505166","phase":"PHASE2","title":"Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases","status":"TERMINATED","sponsor":"Gradalis, Inc.","startDate":"2012-03","conditions":"Colon Cancer","enrollment":3},{"nctId":"NCT04947826","phase":"PHASE2","title":"Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2021-08","conditions":"Hepatocellular Carcinoma With Major Portal Vein Thrombosis","enrollment":100},{"nctId":"NCT01298570","phase":"PHASE2","title":"Regorafenib+FOLFIRI Versus Placebo+FOLFIRI as 2nd Line Tx in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2011-04-07","conditions":"Colorectal Cancer Metastatic","enrollment":181},{"nctId":"NCT04136600","phase":"PHASE2","title":"EGFR Monoclonal Antibody for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Shanghai Changzheng Hospital","startDate":"2019-07-01","conditions":"Gastric Cancer, Cetuximab, Nimotuzumab","enrollment":100},{"nctId":"NCT00612586","phase":"PHASE2","title":"Study of Enzastaurin With 5-Fluorouracil/Leucovorin (5-FU/LV) Plus Bevacizumab as Maintenance Regimen Following First Line Therapy for Metastatic Colon Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2008-02","conditions":"Colorectal Cancer","enrollment":117},{"nctId":"NCT02545504","phase":"PHASE3","title":"Andecaliximab With mFOLFOX6 as First Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-10-13","conditions":"Gastric Adenocarcinoma","enrollment":432},{"nctId":"NCT03780049","phase":"PHASE3","title":"HAIC Plus H101 vs HAIC Alone for Unresectable HCC at BCLC A-B","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2018-10-01","conditions":"Hepatocellular Carcinoma","enrollment":304},{"nctId":"NCT03688230","phase":"PHASE2","title":"Study of Abituzumab in Combination With Cetuximab and FOLFIRI in Patients With Metastatic Colorectal Cancer.","status":"WITHDRAWN","sponsor":"SFJ Pharmaceuticals X, LTD.","startDate":"2019-04","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT01747551","phase":"PHASE2","title":"FOLFOX +/- Ziv-Aflibercept for Esophageal and Gastric Cancer","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-01","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":64},{"nctId":"NCT00056459","phase":"PHASE3","title":"Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.","status":"COMPLETED","sponsor":"Novartis","startDate":"2003-02","conditions":"Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms","enrollment":1168},{"nctId":"NCT02251977","phase":"PHASE3","title":"Effect of GM1 in Prevention of Oxaliplatin Induced Neurotoxicity in Stage II/III Colorectal Cancer","status":"COMPLETED","sponsor":"Yuhong Li","startDate":"2014-09","conditions":"Colorectal Cancer, Chemotherapy-induced Neutropenia","enrollment":196},{"nctId":"NCT01183780","phase":"PHASE3","title":"A Study in Second Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2010-12-02","conditions":"Colorectal Cancer","enrollment":1072},{"nctId":"NCT01505530","phase":"PHASE2","title":"A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-12","conditions":"Pancreatic Cancer","enrollment":125},{"nctId":"NCT02605044","phase":"PHASE3","title":"Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer","status":"TERMINATED","sponsor":"AB Science","startDate":"2014-01","conditions":"Metastatic Colorectal Cancer","enrollment":123},{"nctId":"NCT02305758","phase":"PHASE2","title":"Study Comparing Veliparib Plus FOLFIRI Versus Placebo Plus FOLFIRI With or Without Bevacizumab in Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-02","conditions":"Untreated Metastatic Colorectal Cancer","enrollment":130},{"nctId":"NCT03607643","phase":"PHASE1, PHASE2","title":"A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies","status":"UNKNOWN","sponsor":"Leaf Vertical Inc.","startDate":"2019-01-15","conditions":"Cancer of Pancreas, Cancer of Liver, Cancer of Rectum","enrollment":160},{"nctId":"NCT01619423","phase":"PHASE1, PHASE2","title":"A Trial of PledOx + FOLFOX6 Compared to Placebo + FOLFOX6 in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Egetis Therapeutics","startDate":"2012-09","conditions":"Advanced Metastatic (Stage IV) Colorectal Cancer","enrollment":186},{"nctId":"NCT03426371","phase":"PHASE3","title":"Epidermal Growth Factor Receptor (EGFR) Antagonist Chimeric Anti-EGFR Monoclonal Antibody Trial","status":"UNKNOWN","sponsor":"Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.","startDate":"2018-02","conditions":"Metastatic Colorectal Cancer","enrollment":570},{"nctId":"NCT03389659","phase":"PHASE3","title":"XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2018-02","conditions":"Vitamin D3","enrollment":750},{"nctId":"NCT00911170","phase":"PHASE3","title":"PAVES: Pegfilgrastim Anti-vascular Endothelial Growth Factor (VEGF) Evaluation Study","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-11-03","conditions":"Cancer, Colon Cancer, Colorectal Cancer","enrollment":847},{"nctId":"NCT00636610","phase":"PHASE2","title":"A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2008-05","conditions":"Metastatic Colorectal Cancer","enrollment":199},{"nctId":"NCT01418222","phase":"PHASE2","title":"FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-09-14","conditions":"Colorectal Cancer","enrollment":194},{"nctId":"NCT02856867","phase":"PHASE2","title":"Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN)","status":"WITHDRAWN","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2016-12","conditions":"Esophagogastric Adenocarcinoma, Metastatic Disease, No Previous Chemotherapy for Metastatic Esophagogastric Cancer","enrollment":""},{"nctId":"NCT00056446","phase":"PHASE3","title":"Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2003-01","conditions":"Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms","enrollment":855},{"nctId":"NCT00399035","phase":"PHASE3","title":"Cediranib (AZD2171, RECENTIN™) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2006-11","conditions":"Metastatic Colorectal Cancer","enrollment":1254},{"nctId":"NCT01662869","phase":"PHASE3","title":"A Study of Onartuzumab in Combination With mFOLFOX6 in Participants With Metastatic HER2-Negative and MET-Positive Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-11","conditions":"Gastric Cancer","enrollment":564},{"nctId":"NCT00813605","phase":"PHASE2","title":"QUILT-2.018: Safety & Efficacy of FOLFIRI With AMG 479 or AMG 655 vs FOLFIRI Alone in KRAS-mutant Metastatic Colorectal Carcinoma","status":"COMPLETED","sponsor":"NantCell, Inc.","startDate":"2009-03","conditions":"Metastatic Colorectal Cancer","enrollment":155},{"nctId":"NCT02813096","phase":"NA","title":"Study of Folfox4 Chemotherapy Regimen to Prevent Early Postoperative Recurrence for HCC-PVTT Patients","status":"UNKNOWN","sponsor":"Guangxi Medical University","startDate":"2016-10","conditions":"Carcinoma, Hepatocellular","enrollment":500},{"nctId":"NCT01085331","phase":"PHASE1, PHASE2","title":"MEK Inhibitor MSC1936369B Plus FOLFIRI in Second Line K-Ras Mutated Metastatic Colorectal Cancer (mCRC)","status":"TERMINATED","sponsor":"EMD Serono","startDate":"2010-03","conditions":"Metastatic Colorectal Cancer","enrollment":16},{"nctId":"NCT01661270","phase":"PHASE3","title":"A Study of Aflibercept Versus Placebo With FOLFIRI in Patients With Metastatic Colorectal Cancer Previously Treated With an Oxaliplatin Chemotherapy","status":"COMPLETED","sponsor":"Sanofi","startDate":"2012-07","conditions":"Colorectal Cancer Metastatic","enrollment":332},{"nctId":"NCT00069095","phase":"PHASE3","title":"A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2003-07","conditions":"Colorectal Cancer","enrollment":2035},{"nctId":"NCT01399684","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2011-11","conditions":"Metastatic Colorectal Cancer","enrollment":127},{"nctId":"NCT01590719","phase":"PHASE2","title":"A Study of Onartuzumab (MetMAb) in Combination With mFOLFOX6 in Patients With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2) Negative Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-07","conditions":"Gastric Cancer","enrollment":123},{"nctId":"NCT00305188","phase":"PHASE3","title":"Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-12","conditions":"Metastases, Colorectal Neoplasms, Colorectal Carcinoma","enrollment":879},{"nctId":"NCT00982592","phase":"PHASE2","title":"Combination Chemotherapy With or Without Vismodegib in Treating Patients With Advanced Stomach Cancer or Gastroesophageal Junction Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2009-09","conditions":"Adenocarcinoma of the Gastroesophageal Junction, Adenocarcinoma of the Stomach, Recurrent Gastric Cancer","enrollment":124},{"nctId":"NCT02590367","phase":"PHASE2, PHASE3","title":"Estimate the Efficacy of HD6610 Granule for Oxaliplatin-induced Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Jiangsu Province Hospital of Traditional Chinese Medicine","startDate":"2015-08","conditions":"Peripheral Neuropathy","enrollment":64},{"nctId":"NCT00851045","phase":"PHASE2","title":"Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2009-10","conditions":"Colorectal Cancer (CRC)","enrollment":17},{"nctId":"NCT00752570","phase":"PHASE2","title":"A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma","status":"COMPLETED","sponsor":"Amgen","startDate":"2008-11","conditions":"Cancer, Carcinoma, Colon Cancer","enrollment":144},{"nctId":"NCT02510118","phase":"PHASE2, PHASE3","title":"Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients","status":"UNKNOWN","sponsor":"Nanjing NingQi Medicine Science and Technology Co., Ltd.","startDate":"2015-06","conditions":"Colon Cancer","enrollment":360},{"nctId":"NCT00457691","phase":"PHASE3","title":"Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2007-06","conditions":"Metastatic Colorectal Cancer","enrollment":768},{"nctId":"NCT00865709","phase":"PHASE2","title":"Study of Modified FOLFOX6 Plus or Minus Sorafenib in Stage IV Metastatic Colorectal Carcinoma (mCRC) Subjects","status":"COMPLETED","sponsor":"Bayer","startDate":"2009-03","conditions":"Metastatic Colorectal Cancer","enrollment":198},{"nctId":"NCT01246960","phase":"PHASE2","title":"A Study of Ramucirumab in Participants With Gastric, Esophageal, and Gastroesophageal Cancer","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Stomach Cancer, Esophageal Cancer","enrollment":168},{"nctId":"NCT00393822","phase":"PHASE2, PHASE3","title":"A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-08","conditions":"Colon Cancer","enrollment":100},{"nctId":"NCT00625651","phase":"PHASE1, PHASE2","title":"Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Amgen","startDate":"2007-10","conditions":"Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer","enrollment":202},{"nctId":"NCT00494221","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Cediranib (AZD2171) in Japanese Metastatic Colorectal Cancer Patients in Combination With FOLFOX","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-06","conditions":"Metastatic Colorectal Cancer","enrollment":172},{"nctId":"NCT01786538","phase":"PHASE3","title":"Second-line FOLFOX With or Without Regorafenib in mCRC Patients Failed to First-line Irinotecan Plus Fluoropyrimidines","status":"WITHDRAWN","sponsor":"Asan Medical Center","startDate":"2013-06","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT00889343","phase":"PHASE2","title":"Study to Evaluate the Effects of Sorafenib if Combined With Chemotherapy (FOLFOX6 or FOLFIRI) in the Second-Line Treatment of Colorectal Cancer","status":"TERMINATED","sponsor":"AIO-Studien-gGmbH","startDate":"2009-03","conditions":"Colorectal Neoplasms","enrollment":101},{"nctId":"NCT00070122","phase":"PHASE3","title":"Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2004-04","conditions":"Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum, Recurrent Colon Cancer","enrollment":2200},{"nctId":"NCT00561470","phase":"PHASE3","title":"Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen","status":"COMPLETED","sponsor":"Sanofi","startDate":"2007-11","conditions":"Colorectal Neoplasms, Neoplasm Metastasis","enrollment":1226},{"nctId":"NCT01175291","phase":"PHASE2","title":"FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer","status":"WITHDRAWN","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2010-09","conditions":"Metastatic Colorectal Cancer","enrollment":""},{"nctId":"NCT00065117","phase":"PHASE2","title":"Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2003-09","conditions":"Colorectal Neoplasms, Metastases, Neoplasm","enrollment":180},{"nctId":"NCT00101686","phase":"PHASE3","title":"Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-02","conditions":"Colorectal Neoplasms","enrollment":547},{"nctId":"NCT00037180","phase":"PHASE2","title":"For Prevention of Diarrhea in Patients Diagnosed With Metastatic Colorectal Cancer Treated With Chemotherapy","status":"TERMINATED","sponsor":"Pfizer","startDate":"2002-04","conditions":"Neoplasm Metastasis, Colorectal Neoplasms","enrollment":212},{"nctId":"NCT00036517","phase":"PHASE1, PHASE2","title":"Safety Study of the Chemotherapy Modulator PHY906 in Patients With Advanced Colorectal Cancer","status":"TERMINATED","sponsor":"PhytoCeutica","startDate":"2002-02","conditions":"Colorectal Neoplasms, Diarrhea","enrollment":30}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo、5-Fluorouracil、Leucovorin","genericName":"Placebo、5-Fluorouracil、Leucovorin","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"5-Fluorouracil is a pyrimidine antimetabolite that inhibits thymidylate synthase and gets incorporated into RNA, disrupting nucleotide synthesis and cancer cell division, while leucovorin enhances its efficacy by stabilizing the drug-enzyme complex. Used for Colorectal cancer (adjuvant or metastatic), Gastric cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}